CytomX Therapeutics (CTMX) Other Non-Current Liabilities (2014 - 2026)

CytomX Therapeutics (CTMX) has 10 years of Other Non-Current Liabilities data on file, last reported at $4.4 million in Q1 2026.

• Quarterly Other Non-Current Liabilities rose 5.63% year-over-year to $4.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.4 million (up 5.63% YoY) and the FY2025 annual result came in at $4.4 million, up 5.78% from the prior year.
• Other Non-Current Liabilities improved to $4.4 million in Q1 2026, from $4.4 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $4.4 million in Q1 2026 to a low of $216000.0 in Q2 2023.
• A 4-year average of $3.7 million and a median of $4.1 million in 2024 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2024 — Other Non-Current Liabilities surged 1748.61% — and 2026, when it gained 5.63%.
• Tracing CTMX's Other Non-Current Liabilities over 4 years: stood at $3.9 million in 2023, then grew by 5.7% to $4.1 million in 2024, then climbed by 5.78% to $4.4 million in 2025, then gained by 1.36% to $4.4 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $4.4 million (Q1 2026), $4.4 million (Q4 2025), and $4.3 million (Q3 2025), per Business Quant data.